Clinical trials: Liver Tumour
Liver Malignant Tumors
Clinical Effectiveness of Microwave Ablation Using Starwave Microwave Generator for Hepatic Malignancies
The purpose of this study is to determine the technical success rate of creating a safety margin of 5 mm or more including the tumor by performing image-guided percutaneous microwave thermal therapy using a microwave generator…
- Trial name
- NCT06426992
- Testing
- Starwave Microwave Ablation System, Microwave Ablation, Ultrasound-CT fusion guidance system
- Where
- South Korea
- Volunteers
- 128 people
- Sponsor
- Seoul National University Hospital
Hepatitis C, Hepatocellular Carcinoma
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
The primary objective is to determine if the administration of a combination of sofosbuvir (SOF; GS-7977; PSI-7977) and ribavirin (RBV) to HCV-infected adults with hepatocellular carcinoma (HCC) meeting the MILAN criteria prior…
- Trial name
- NCT01559844
- Testing
- Sofosbuvir, Ribavirin
- Where
- 15 sites in United States, New Zealand and 1 more
- Volunteers
- 61 people
- Sponsor
- Gilead Sciences
Breast Cancer, Hepatitis C
Association of Hepatitis C Virus With Breast Cancer
Hepatitis C viral infection is a major health problem in Egypt. The management of breast cancer patients is often complicated by the presence of associated HCV infection.
- Trial name
- NCT04090164
- Where
- Egypt
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Carcinoma, Hepatocellular
A Study Comparing Radiofrequency Ablation and Hepatic Resection for Hepatocellular Carcinoma
The purpose of this prospective randomized study is to compare the efficacy and safety of radiofrequency ablation and hepatic resection for small hepatocellular carcinomas with very homogeneous underlying conditions.
- Trial name
- NCT02482909
- Testing
- Hepatic resection, Radiofrequency ablation
- Volunteers
- 68 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma
Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma
Though hepatectomy is one of the curative treatment for patients with hepatocellular carcinoma (HCC), the 5-years recurrence-free survival is lower than 30%.
- Trial name
- NCT05221398
- Testing
- Immune Checkpoint Inhibitors Based Adjuvant therapy, Active surveillance
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Guangxi Medical University
Hepatitis C, Cirrhosis
Incidence of de Novo Hepatocellular Carcinoma After Antiviral Agents for HCV.
The main risk factor for development of hepatocellular carcinoma (HCC) is cirrhosis of any etiology, with an annual incidence risk between 1-6%; currently the leading cause of death in patients with cirrhosis and the 2nd cause of…
- Conditions
- Hepatitis C, Cirrhosis, Antiviral Drug Adverse Reaction
- Trial name
- NCT03775798
- Testing
- Direct antiviral agents for hepatitis C
- Where
- Argentina
- Volunteers
- 2,200 people
- Sponsor
- Austral University, Argentina
Colorectal Cancer Metastatic, Liver Metastases
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
The goal of this clinical trial is to to learn about different combinations of immunotherapy in patients with colorectal cancer whose cancer has spread to their liver and are planning to have surgery to remove tumor metastases…
- Conditions
- Colorectal Cancer Metastatic, Liver Metastases, Colorectal Cancer
- Trial name
- NCT06300463
- Testing
- Botensilimab, Balstilimab, AGEN1423
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Weill Medical College of Cornell University
Unresectable Hepatocellular Carcinoma
TACE With Thermosensitive Nanogel Versus Embosphere for HCC
To verify the safety and efficacy of TACE withThermosensitive Nanogel Embolic Agent for HCC.
- Trial name
- NCT06593964
- Testing
- Thermosensitive Nanogel Embolic Agent
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Zhongda Hospital
Cirrhosis of Liver
Gadoxetic Acid-MRI Versus Ultrasonography for the Surveillance of Hepatocellular Carcinoma in High-risk Patients
Current practice guidelines recommend surveillance for hepatocellular carcinoma (HCC) in liver cirrhosis patients with ultrasonography (USG) every 6 months.
- Trial name
- PRIUS (NCT01446666)
- Where
- South Korea
- Volunteers
- 423 people
- Sponsor
- Asan Medical Center
Hepatocellular Carcinoma(HCC)
Comparing Re-TACE Versus SABR for Post-prior-TACE Incompletely Regressed HCC: a Randomized Controlled Trial (TASABR)
Till now, trans-arterial chemoembolization (TACE) is still one of the common modalities in treating hepatocellular carcinoma patients with unresectable intermediate stage.
- Trial name
- TASABR (NCT02921139)
- Testing
- Stereotactic ablative radiotherapy (SABR), Re-Transcatheter arterial chemoembolization (re-TACE)
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Dalin Tzu Chi General Hospital
Hepatocellular Carcinoma
Radiofrequency Ablation Assisted Hepatectomy Versus Hepatectomy Alone for Advanced Hepatocellular Carcinoma
RFA has become a standard method in the treatment of small HCC(≤2 cm) due to its ease of use, safety, cost-effectiveness, and minimal invasiveness.
- Trial name
- NCT01713244
- Testing
- RFA assisted Hepatectomy, Hepatectomy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Southwest Hospital, China
Liver Cancer, Liver Transplant Disorder
SBRT for Liver Cancer Before Liver Transplantation
Hepatocellular carcinoma (HCC) is the second commonest cause of cancer death worldwide. It is the third leading cause of cancer death in Hong Kong.
- Trial name
- NCT04186234
- Testing
- Stereotactic body radiation therapy
- Where
- Hong Kong
- Volunteers
- 71 people
- Sponsor
- The University of Hong Kong
Hepatocellular Carcinoma (HCC)
Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection
This is a multi-center, randomized, open-label pivotal phase II study to evaluate the efficacy and safety of EAL as adjuvant therapy in preventing recurrence in patients with primary HCC at high recurrence risk after radical…
- Trial name
- NCT05213637
- Testing
- Expanded Activated Lymphocytes (EAL), transarterial chemoembolization (TACE)
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Chinese PLA General Hospital
Hepatocellular Carcinoma
Antiviral Therapy for Patients With Liver Cancer After Surgery
This is a single-center, prospective, observational, real world study designed to evaluate the effects of peginterferon α-2b(pegabin) combined with nucleoside (acid) analogs (entecavir,ETV tenofovir,TDF tenofovir alafenamide,TAF)…
- Trial name
- NCT05466565
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Xiangya Hospital of Central South University
Hepatocellular Carcinoma
SNMC (Stronger Neo-Minophagen C ) for Acute Hepatitis Post Transarterial Chemoembolization Therapy
A glycyrrhizin-containing product, Stronger Neo-Minophagen C TM (SNMC; Minophagen Pharmaceutical Co.Ltd.,Tokyo,Japan),is widely used in Japan for suppression of hepatitis activity and for prevention of disease progression in…
- Trial name
- NCT04015245
- Testing
- Stronger Neo-Minophagen C
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Chimei Medical Center
Primary Liver Cancer, Liver Metastasis
Evaluation of Preoperative Investigations in Patients With Liver Cancer
The aim of the study is to evaluate the diagnostic procedures emission tomography in combination with a CT scan (PET/CT) and endoscopic ultrasonography (EUS) in the preoperative evaluation of resectability of patients with…
- Trial name
- NCT00408122
- Testing
- PET/CT scan and EUS
- Where
- Denmark
- Volunteers
- 77 people
- Sponsor
- Odense University Hospital
Hepatocellular Carcinoma
Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
The purpose of this study is to investigate the efficacy and safety of lenvatinib plus nivolumab compared with lenvatinib monotherapy for patients with advanced hepatitis B virus infection-related hepatocellular carcinoma.
- Trial name
- NCT04044651
- Testing
- Lenvatinib, Nivolumab
- Where
- 5 sites in China
- Sponsor
- Shi Ming
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Hepatocellular Carcinoma
A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
This is an open label, multi-center, single arm study to evaluate the efficacy and safety of tislelizumab combined with sitravatinib as adjuvant therapy in hepatocellular carcinoma (HCC) patients who are at high risk of…
- Trial name
- NCT05407519
- Testing
- Tislelizumab + Sitravatinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Anhui Provincial Hospital
Resectable Hepatic Metastases of Colorectal Cancer
Study of Immune Response and Liver Damage Induced by Chemotherapy for Liver Metastases of Colorectal Cancer
The immune response at primary tumor has a major role in the prognosis of colorectal cancer (CRC). Some studies suggest a prognosis value of cytotoxic T cell and memory T cells at primary tumor greater than tumoral stage.
- Trial name
- METAHEP (NCT01673607)
- Testing
- Biopsie liver
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Poitiers University Hospital
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.